SLA Pharma's EPA free fatty acid reduces colonic polyps
This article was originally published in Scrip
SLA Pharma's free fatty acid form of eicosapentaenoic acid (EPA), Alfa, has achieved statistically significant reductions in the number and size of colonic polyps in a late-stage clinical study in patients with familial adenomatous polyposis (FAP).
You may also be interested in...
UCB's R&D efforts include late-stage diverse but complementary immunologicals and anti-neuroinflammatories.
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.